MINNEAPOLIS--(BUSINESS WIRE)--MGI PHARMA, INC. (Nasdaq:MOGN), a biopharmaceutical company focused in oncology and acute care, announced that the New Drug Application (NDA) for Aquavan® (fospropofol disodium) Injection has been submitted to the U.S. Food and Drug Administration (FDA) for review. Aquavan is an investigational drug that is being studied as a sedative-hypnotic agent in patients undergoing brief surgical or diagnostic procedures.
